Latest news articles

Added 1 month ago Drug news

Gantenerumab arm of the phase II/III DIAN-TU-001 study did not meet its primary endpoint for early- onset Alzheimer's disease.- Roche

Roche has announced that the gantenerumab arm of the Phase II/III DIAN-TU-001 study did not meet its primary endpoint in...

Added 1 month ago Drug news

Analysis of DIAN-TU study showed that solanezumab did not meet the primary endpoint for Alzheimers disease- Eli Lilly.

Eli Lilly and Company announced that the analysis performed by Washington University School of Medicine in the Dominantly Inherited Alzheimer...

Added 5 months ago Drug news

Biogen plans regulatory filing at FDA for aducanumab in Alzheimer's disease based on new phase III analyses.

Biogen announced that, after consulting with the FDA, Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for...

Search all news articles for Alzheimer's disease and dementia
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Optimising anti-TNF treatment using biosimilars

Optimising anti-TNF treatment using biosimilars

Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

Guidelines

Delirium: prevention, diagnosis and management

This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and...

Added 7 months ago

Risk reduction and management of delirium

This guideline provides recommendations based on current evidence for best practice in the detection, assessment, treatment and follow up of adults with delirium, as well as reducing the risk of delirium.

Added 7 months ago

Dementia: assessment, management and support for people living with dementia and their carers

This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.

Added 7 months ago

Search all guidelines for Alzheimer's disease and dementia
 

Journal articles

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.

Objectives: To compare the efficacy, safety and tolerability of a novel rivastigmine transdermal patch with conventional rivastigmine capsules and placebo in patients with Alzheimer's disease (AD).

Added 2 months ago

EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia.

Background and objectives: The last version of the EFNS dementia guidelines is from 2007. In 2010, the revised guidelines for Alzheimer's disease (AD) were published. The current guidelines involve the revision of the dementia...

Added 2 months ago

Assessment scales in dementia.

Dementia involves progressive and often remorseless decline in cognition, function, behaviour and care needs. Assessment in dementia relies on collateral as well as patient-derived information. Many assessment scales have been developed...

Added 2 months ago

Search all journal articles for Alzheimer's disease and dementia
 

Clinical trials

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (AscenD-LB)

This is a Phase 2, multi-center, randomized, double-blind, placebo-controlled, proof-of-principle study of neflamapimod versus matching placebo (randomized 1:1) administered with food for 16 weeks in subjects with DLB.

Added 4 months ago

A Study to Evaluate Safety of Long-term AL001 Dosing in FTD Patients

A Phase 2 open label study evaluating the safety, tolerability, PK and PD of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.

Added 4 months ago

PTI-125 for Mild-to-moderate Alzheimer's Disease Patients

This is a Phase 2b, Randomized, Double-blind, Placebo-controlled, multiple dose study of PTI-125 in mild-to-moderate Alzheimer's disease patients. A total of sixty (60) patients will be enrolled in the study.

Added 5 months ago

Search all clinical trials for Alzheimer's disease and dementia
 
Dr Cornelia Meisenberg

Dr Conny Meisenberg is a medical writer at EPG Health. She joined EPG Health in 2019 following 7 years of postdoctoral research in the oncology field.

Progressive Supranuclear Palsy (PSP)

What is Progressive Supranuclear Palsy (PSP)? Review the causes, treatment and current trials for this uncommon, degenerative disorder.

CME

Diabetes care, antivirals for flu and dementia risk: update clinical February 2016

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0

Hallucinations - red flag symptoms

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
0
Registration required
1
Subscription fee
0

Alzheimer's disease: clinical review

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0
Search all CME for Alzheimer's disease and dementia